心肌收缩调节器在心力衰竭患者中的短期疗效与安全性
该横断面研究纳入9例接受CCM置入的心衰患者,随访3个月。结果显示LVEF和6分钟步行距离显著改善,无再入院、恶性心律失常或相关并发症,提示CCM短期安全有效。
要点
- CCM置入后3个月LVEF和6分钟步行距离较术前显著改善
- NYHA Ⅲ~Ⅳ级比例下降但差异无统计学意义
- 无再入院、恶性心律失常及囊袋/电极等相关并发症
核心结论
- CCM在心力衰竭患者中具有较好的短期安全性及有效性。
研究设计与样本
- 横断面研究,纳入2022年2至6月于新疆医科大学第一附属医院接受CCM置入的心力衰竭患者9例,随访3个月。
主要发现
- 9例均成功置入CCM,男性7例,年龄(56±14)岁,缺血性心肌病3例,扩张性心肌病6例。
- 术后3个月LVEF较术前升高[(38.3±4.3)%比(29.4±5.2)%,P<0.05]。
- 6分钟步行试验距离较术前延长[(289.3±121.7)m比(96.8±66.7)m,P<0.05]。
- NYHA Ⅲ~Ⅳ级患者比例下降但差异无统计学意义(2/9比7/9,P>0.05)。
- 无因心衰加重再入院、无恶性心律失常,未发现囊袋血肿、感染、电极脱落、瓣膜功能损害、心包积液或心脏穿孔等并发症。
关键数值与推荐
- 术后3个月右心室感知较术中下降[(8.2±1.1)mV比(16.3±7.0)mV,P<0.05]。
- 局部感知电极感知较术中下降[(6.7±2.5)mV比(15.7±4.9)mV,P<0.05]。
- 右心室阻抗较术中下降[(470±65)Ω比(846±179)Ω,P<0.05]。
- 局部感知电极阻抗较术中下降[(464±63)Ω比(832±246)Ω,P<0.05]。
- CCM输出百分比(86.9±10.7)%,输出幅度(6.7±0.4)V,工作时间(8.6±1.0)h/d。
临床怎么用
- CCM可作为心衰患者改善短期心功能和生活质量的器械治疗选择。
- 术后3个月内需监测CCM感知、阻抗、输出百分比和工作时间。
局限性
- 样本量小(9例),随访仅3个月,为单中心横断面研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the short-term efficacy and safety of cardiac contractility modulation (CCM) in patients with heart failure. Methods: This was a cross-sectional study of patients with heart failure who underwent CCM placement at the First Affiliated Hospital of Xinjiang Medical University from February to June 2022. With a follow-up of 3 months, CCM sensation, impedance, percent output, and work time were monitored, and patients were compared with pre-and 3-month postoperative left ventricular ejection fraction (LVEF) values, and 6-minute walk test distance and New York Heart Association (NYHA) cardiac function classification, and the occurrence of complications was recorded. Results: CCM was successfully implanted in all 9 patients. Seven(7/9) of them were male, aged (56±14) years, 3 patients had ischaemic cardiomyopathy and 6 patients had dilated cardiomyopathy. At 3-month postoperative follow-up, threshold was stable, sense was significantly lower at follow-up than before (right ventricle: (16.3±7.0) mV vs. (8.2±1.1) mV, P<0.05; local sense: (15.7±4.9) mV vs. (6.7±2.5) mV, P<0.05), and impedance was significantly lower at follow-up than before (right ventricle (846±179) Ω vs. (470±65) Ω, P<0.05, local sense: (832±246) Ω vs. (464±63) Ω, P<0.05). The CCM output percentage was (86.9±10.7) %, the output amplitude was (6.7±0.4) V, and the daily operating time was (8.6±1.0) h. LVEF was elevated compared to preoperative ((29.4±5.2) % vs. (38.3±4.3) %, P<0.05), the 6-minute walk test was significantly longer than before ((96.8±66.7)m vs. (289.3±121.7)m, P<0.05). No significant increase in the number of NYHA Class Ⅲ-Ⅳ patients was seen (7/9 vs. 2/9, P>0.05). The patient was not re-hospitalised for worsening heart failure symptoms, had no malignant arrhythmic events and experienced significant relief of symptoms such as chest tightness and shortness of breath. No postoperative complications related to pocket hematoma, pocket infection and rupture, electrode detachment, valve function impairment, pericardial effusion, or cardiac perforation were found. Conclusions: CCM has better short-term safety and efficacy in patients with heart failure. 目的: 探讨心肌收缩调节器(CCM)在心力衰竭患者中的短期有效性及安全性。 方法: 该研究为横断面研究,纳入2022年2至6月于新疆医科大学第一附属医院接受CCM置入的心力衰竭患者。随访3个月,监测CCM感知、阻抗、输出百分比、工作时间,比较患者术前及术后3个月左心室射血分数值(LVEF)、6 min步行试验距离和纽约心脏协会(NYHA)心功能分级,记录并发症及不良事件发生情况。 结果: 纳入的9例患者均成功置入CCM。其中男性7例,年龄(56±14)岁,3例患者为缺血性心肌病,6例患者为扩张性心肌病。术后3个月随访结果显示,CCM阈值平稳,感知较术中下降[右心室:(8.2±1.1)mV比(16.3±7.0)mV,P<0.05;局部感知电极:(6.7±2.5)mV比(15.7±4.9)mV,P<0.05],阻抗较术中明显下降[右心室:(470±65)Ω比(846±179)Ω,P<0.05;局部感知电极:(464±63)Ω比(832±246)Ω,P<0.05];CCM输出百分比为(86.9±10.7)%,输出幅度为(6.7±0.4)V,工作时间为(8.6±1.0)h/d。患者LVEF较术前升高[(38.3±4.3)%比(29.4±5.2)%,P<0.05],6 min步行试验距离较术前延长[(289.3±121.7)m比(96.8±66.7)m,P<0.05],NYHA Ⅲ~Ⅳ级患者比例下降,但差异无统计学意义(2/9比7/9,P>0.05)。患者未有因心力衰竭症状加重再次入院,无恶性心律失常事件发生,且胸闷、气短等症状明显缓解。术后未发现囊袋血肿、囊袋感染及破溃、电极脱落、瓣膜功能损害、心包积液、心脏穿孔等相关并发症。 结论: CCM具有较好的短期安全性及有效性。.
引用
- Guo, Shang, Sun, et al. [Short-term efficacy and safety of cardiac contractility modulation in patients with heart failure]. Zhonghua Xin Xue Guan Bing Za Zhi. 2024. PMID: 38644254. doi:10.3760/cma.j.cn112148-20231009-00274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。